Lilly (NYSE:LLY) has also applied to have Omvoh approved by the FDA for the treatment of moderately to severely active Crohn's disease. A decision expected in the first half of 2025.

Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's disease, extending its use beyond ulcerative colitis (UC) for the first time.

Omvoh is currently approved in more than 44 countries, including the United States and Europe, to treat adults with moderate-to-severely active ulcerative colitis (“UC”). LLY Stock’s Performance ...

Newer products (products launched from 2022 onwards) like Ebglyss, Jaypirca and Omvoh are likely to have contributed to sales growth. Sales of the new Alzheimer’s drug Kisunla (donanemab ...

Other than Mounjaro and Zepbound, Lilly has gained approvals for some other new drugs in the past couple of years across different therapeutic areas like Omvoh, Jaypirca, Ebglyss and Kisunla ...

Lilly said the new drug – which will be sold under the Omvoh brand – will be launched in the coming weeks. It has already been approved under the same trade name in Europe and Japan ...

2.0%). The company received approvals for some new drugs like Kisunla, Omvoh and Jaypirca over the past two years, which has boosted its performance. The new drugs contributed significantly to top ...